ArticleMMWR. Morbidity and mortality weekly report2024
COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥18 Years - COVID-NET, 12 States, October 2023-April 2024.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287137 (IDCRP-154), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Who cites it
21 citing papers in PubMed.
- Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.The Journal of infectious diseases · 2026Trial
- Codesigning COVID-19 booster promotion materials in online workshops with long-term care staff: a process evaluation.Health education research · 2026Trial
- Rethinking seasonal COVID-19 vaccination in the endemic era: summer timing, eligibility, and frequency in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Viral Pathogen-Specific Severe Acute Respiratory Infections in Hospitalised Adults in Europe: Epidemiological Findings from the id.DRIVE Study 2024-2025.Infectious diseases and therapy · 2026Article
- A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.Molecular therapy. Advances · 2026Article
- Article
- Effectiveness of COVID-19 Vaccines Against Hospitalization and Severe Disease in Children with Diabetes Mellitus During Pandemic and Post-Pandemic Eras.Microorganisms · 2026Article
- Qualitative analysis of COVID-19 experiences with testing and vaccination among people with systemic lupus erythematosus in the USA.Clinical rheumatology · 2026Article
- SARS-CoV-2 outbreaks in long-term care facilities during the Omicron era in Québec, Canada.Scientific reports · 2025Article
- Developing a Latin American Delphi Consensus on Vaccination for Respiratory Diseases in Older Adults.Annals of geriatric medicine and research · 2025Article
- Nationwide survey of municipal policies and COVID-19 vaccination uptake among older adults in Japan during 2024-2025.Human vaccines & immunotherapeutics · 2025Article
- Exploring long-term recovery and community health management: a qualitative study of older adults and caregivers' experiences post COVID-19 in the Republic of Ireland.BMC geriatrics · 2025Article
- Boost your health (Refuerza tu Salud): Design of a randomized controlled trial of a community health worker intervention to reduce inequities in COVID-19 and influenza vaccinations.Contemporary clinical trials · 2025Article
- Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19.Microbiology spectrum · 2025Article
- Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.MMWR. Morbidity and mortality weekly report · 2025Article
- Multidimensional Demographic Analyses of COVID-19 Vaccine Inequality in the United States: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Association between SARS-CoV-2 in wastewater and COVID-19 hospitalizations in three countries, 2022-2024.Frontiers in public health · 2025Article
- Resource utilisation and cost of hospitalisation with community-acquired pneumonia among older adults in India, 2018-2020.BMJ public health · 2025Article
- The immunological impact of revaccination in a hybrid-immune world.Frontiers in immunology · 2025Review
- First real-life data on COVID-19 vaccine effectiveness against hospitalisation and severe disease from the eastern part of the WHO European Region.The Lancet regional health. Europe · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among adults, COVID-19 hospitalization rates increase with age. Data from the COVID-19-Associated Hospitalization Surveillance Network were analyzed to estimate population-based COVID-19-associated hospitalization rates during October 2023-April 2024 and identify demographic and clinical characteristics of adults aged ≥18 years hospitalized with COVID-19. Adults aged ≥65 years accounted for 70% of all adult COVID-19-associated hospitalizations, and their COVID-19-associated hospitalization rates were higher than those among younger adult age groups. Cumulative rates of COVID-19-associated hospitalization during October 2023-April 2024 were the lowest for all adult age groups during an October-April surveillance period since 2020-2021. However, hospitalization rates among all adults aged ≥75 years approached one COVID-19-associated hospitalization for every 100 persons. Among adults hospitalized with COVID-19, 88.1% had not received the 2023-2024 formula COVID-19 vaccine before hospitalization, 80.0% had multiple underlying medical conditions, and 16.6% were residents of long-term care facilities (LTCFs). Guidance for adults at high risk for severe COVID-19 illness, including adults aged ≥65 years and residents of LTCFs, should continue to focus on adopting measures to reduce risk for contracting COVID-19, advocating for receipt of recommended COVID-19 vaccinations, and seeking prompt outpatient antiviral treatment after receipt of a positive SARS-CoV-2 test result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.